APP and Alzheimer disease: In this study, we used an APP/PS1 mouse model for AD, which confirms significant cognitive losses that are recovered in NLRP3-deficient mice, to evaluate the therapeutic potential of an orally bioavailable and safe NLRP3 inhibitor, OLT1177.